What are Becton Dickinson's main business segments?

Becton Dickinson's operations are divided into three worldwide business segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. These segments cover a broad range of medical supplies, devices, laboratory equipment, and diagnostic products.

What are the key risks BDX faces according to the filing?

BDX identifies several key risks, including regional and global economic factors, fluctuations in foreign currency exchange rates, competitive product and pricing pressures, changes in domestic and foreign healthcare policies, the cost and availability of raw materials, government regulations, difficulties in product development and obtaining regulatory approvals, and significant litigation.

What is the status of the legal proceedings mentioned in the filing?

BDX is involved in several legal proceedings, most notably product liability lawsuits related to natural rubber latex gloves and alleged needlestick injuries. The company is actively defending these lawsuits and believes that insurance policies will cover a substantial portion of defense costs and potential liabilities. The company is also a defendant in an antitrust lawsuit filed by Retractable Technologies, Inc. (RTI).

Did BDX make any significant accounting changes in fiscal year 2001?

Yes, BDX adopted Staff Accounting Bulletin No. 101 (SAB 101) in the fourth quarter of fiscal year 2001. This change affected revenue recognition for instruments in the Biosciences segment (recognized upon installation) and for branded insulin syringe products sold under incentive programs to distributors (recognized upon sell-through).

BDX 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) filed its 2001 10-K on December 20, 2001, for the fiscal year ended September 30, 2001. The company operates in three global segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences. BDX is a leading global manufacturer and seller of medical supplies, devices, laboratory equipment, and diagnostic products. The filing details BDX's business operations, competitive landscape, and legal proceedings. BDX's extensive global presence, with manufacturing and sales operations in numerous countries, is a key aspect of its business. The company emphasizes its commitment to research and development, investing $212 million in fiscal year 2001 to maintain its competitive edge in the dynamic medical technology field. However, BDX also faces significant risks including economic factors, competitive pressures, healthcare industry changes, raw material costs, regulatory compliance, and litigation.

Key Highlights

1BDX operates through three main business segments: Medical Systems, Clinical Laboratory Solutions, and Biosciences, offering a diverse range of medical and laboratory products.

2The company has a significant global footprint with manufacturing facilities in 17 countries and sales operations worldwide.

3BDX invested $212 million in research and development in fiscal year 2001, highlighting its commitment to innovation and product development.

4The company is a defendant in several significant legal proceedings, including product liability lawsuits related to natural rubber latex gloves and needlestick injuries, with insurance expected to cover a substantial portion of defense costs and potential liabilities.

5BDX adopted Staff Accounting Bulletin No. 101 (SAB 101) during the fourth quarter of fiscal year 2001, impacting revenue recognition for instruments in the Biosciences segment and for branded insulin syringe products sold under incentive programs.

6The company faces various risk factors including regional economic conditions, foreign currency fluctuations, competitive pricing pressures, changes in healthcare regulations, and potential litigation.

BECTON DICKINSON & CO Annual Report, Year Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions